Indian Journal of Medical and Paediatric Oncology

REVIEW ARTICLE
Year
: 2010  |  Volume : 31  |  Issue : 1  |  Page : 8--17

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?


Nirmal V Raut1, Nilesh Chordiya2 
1 Department of Medical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India
2 Department of Surgical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India

Correspondence Address:
Nirmal V Raut
18/144, Anand Nagar, Santacruz (East), Mumbai - 400 055
India

Neoadjuvant chemotherapy (NACT) in breast cancer has undergone continuous evolution over the last few decades to establish its role in the combined modality management of these tumors. The process of evolution is still far from over. Many questions are still lurking in the minds of oncologists treating breast cancer. This review analyzes the evidence from metaanlyses, major multiinstitutional prospective trials, retrospective institutional series and systematic reviews in breast cancer to determine the current standards and controversies in NACT. The most effective drugs, their advantages, issues and controversies in delivery as well as the criteria for response are reviewed. A summary of evidence-based consensus is presented and unresolved aspects are discussed.


How to cite this article:
Raut NV, Chordiya N. NEO adjuvant chemotherapy in breast cancer: What have we learned so far?.Indian J Med Paediatr Oncol 2010;31:8-17


How to cite this URL:
Raut NV, Chordiya N. NEO adjuvant chemotherapy in breast cancer: What have we learned so far?. Indian J Med Paediatr Oncol [serial online] 2010 [cited 2019 May 20 ];31:8-17
Available from: http://www.ijmpo.org/article.asp?issn=0971-5851;year=2010;volume=31;issue=1;spage=8;epage=17;aulast=Raut;type=0